Alliance Global Partners analyst Ben Haynor lowered the firm’s price target on Precipio to $2 from $2.85 and keeps a Buy rating on the shares. Precipio this morning announced an “intriguing” collaboration agreement with an undisclosed “prestigious New York-based institution” to develop a “revolutionary brain tumor panel” using the company’s HemeScreen technology, the analyst tells investors in a research note. The reduction in the target stems from reduced 2024 estimates and the increase in share count that has taken place, says the firm.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on PRPO:
- Precipio’s Omnia™ Methodology Enables Diagnosis of MDS With Peripheral Blood Instead of Bone Marrow Biopsy
- Precipio enters collaboration with academic healthcare institution
- Precipio Enters into Collaboration with Prestigious New York-based Institution to Develop Revolutionary Brain Tumor Panel using HemeScreen® Technology
- Precipio, Inc. Announces Pricing of $2 Million Registered Direct Offering and Concurrent Private Placement
- Projected cash burn reduced by $1.5 million annually from Three Operational Efficiency Projects